Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration
Status:
Terminated
Trial end date:
2019-08-16
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess the safety and tolerability of ascending doses of SAR422459 in participants with
Stargardt's Macular Degeneration (SMD).
Secondary Objective:
To evaluate for possible biological activity of SAR422459.